|
Name |
(3S,4S,9R,10R,13R,14R,17R)-3,4-dihydroxy-17-[(2R)-7-methoxy-6-methyl-5-methylideneheptan-2-yl]-10,13-dimethyl-1,2,3,4,5,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-6-one
|
Molecular Formula | C29H46O4 | |
IUPAC Name* |
(3S,4S,9R,10R,13R,14R,17R)-3,4-dihydroxy-17-[(2R)-7-methoxy-6-methyl-5-methylideneheptan-2-yl]-10,13-dimethyl-1,2,3,4,5,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-6-one
|
|
SMILES |
C[C@H](CCC(=C)C(C)COC)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3C2=CC(=O)C4[C@@]3(CC[C@@H]([C@H]4O)O)C)C
|
|
InChI |
InChI=1S/C29H46O4/c1-17(19(3)16-33-6)7-8-18(2)21-9-10-22-20-15-25(31)26-27(32)24(30)12-14-29(26,5)23(20)11-13-28(21,22)4/h15,18-19,21-24,26-27,30,32H,1,7-14,16H2,2-6H3/t18-,19?,21-,22+,23+,24+,26?,27-,28-,29-/m1/s1
|
|
InChIKey |
XCLVYKBMNARCLH-NOZAKVEFSA-N
|
|
Synonyms |
3beta,4alpha-dihydroxy-26-methoxyergosta-7,24(28)-dien-6-one
|
|
CAS | NA | |
PubChem CID | 138393246 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 458.7 | ALogp: | 5.6 |
HBD: | 2 | HBA: | 4 |
Rotatable Bonds: | 7 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 66.8 | Aromatic Rings: | 4 |
Heavy Atoms: | 33 | QED Weighted: | 0.489 |
Caco-2 Permeability: | -4.831 | MDCK Permeability: | 0.00001720 |
Pgp-inhibitor: | 0.988 | Pgp-substrate: | 0.012 |
Human Intestinal Absorption (HIA): | 0.011 | 20% Bioavailability (F20%): | 0.825 |
30% Bioavailability (F30%): | 0.175 |
Blood-Brain-Barrier Penetration (BBB): | 0.46 | Plasma Protein Binding (PPB): | 94.53% |
Volume Distribution (VD): | 1.086 | Fu: | 2.13% |
CYP1A2-inhibitor: | 0.015 | CYP1A2-substrate: | 0.462 |
CYP2C19-inhibitor: | 0.035 | CYP2C19-substrate: | 0.883 |
CYP2C9-inhibitor: | 0.118 | CYP2C9-substrate: | 0.115 |
CYP2D6-inhibitor: | 0.003 | CYP2D6-substrate: | 0.856 |
CYP3A4-inhibitor: | 0.45 | CYP3A4-substrate: | 0.549 |
Clearance (CL): | 6.5 | Half-life (T1/2): | 0.122 |
hERG Blockers: | 0.015 | Human Hepatotoxicity (H-HT): | 0.187 |
Drug-inuced Liver Injury (DILI): | 0.338 | AMES Toxicity: | 0.021 |
Rat Oral Acute Toxicity: | 0.85 | Maximum Recommended Daily Dose: | 0.181 |
Skin Sensitization: | 0.182 | Carcinogencity: | 0.042 |
Eye Corrosion: | 0.004 | Eye Irritation: | 0.02 |
Respiratory Toxicity: | 0.844 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC005968 | 0.560 | D0M4WA | 0.410 | ||||
ENC001603 | 0.560 | D0G3SH | 0.403 | ||||
ENC002718 | 0.458 | D03ZTE | 0.403 | ||||
ENC000609 | 0.403 | D0Y7LD | 0.352 | ||||
ENC005630 | 0.403 | D0OR2L | 0.341 | ||||
ENC004735 | 0.393 | D08SVH | 0.323 | ||||
ENC005016 | 0.372 | D0K5WS | 0.323 | ||||
ENC004804 | 0.370 | D0T2PL | 0.313 | ||||
ENC001984 | 0.370 | D02VPX | 0.308 | ||||
ENC005438 | 0.370 | D02ZGI | 0.303 |